Hims & Hers Health, Inc. $HIMS Stock Holdings Lifted by Farallon Capital Management LLC

Farallon Capital Management LLC lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 10,746,852 shares of the company’s stock after purchasing an additional 2,533,271 shares during the quarter. Hims & Hers Health comprises 2.5% of Farallon Capital Management LLC’s investment portfolio, making the stock its 9th biggest position. Farallon Capital Management LLC’s holdings in Hims & Hers Health were worth $609,561,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in HIMS. Clear Street Group Inc. acquired a new position in Hims & Hers Health during the third quarter worth $87,372,000. Bank of Nova Scotia purchased a new stake in Hims & Hers Health in the 3rd quarter valued at $1,317,000. Aquatic Capital Management LLC acquired a new stake in shares of Hims & Hers Health in the 3rd quarter worth $5,233,000. Alliancebernstein L.P. increased its stake in shares of Hims & Hers Health by 0.4% in the 3rd quarter. Alliancebernstein L.P. now owns 500,106 shares of the company’s stock worth $28,366,000 after acquiring an additional 1,784 shares during the last quarter. Finally, Creative Planning raised its holdings in shares of Hims & Hers Health by 9.2% during the 3rd quarter. Creative Planning now owns 99,281 shares of the company’s stock worth $5,631,000 after acquiring an additional 8,375 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity

In related news, CFO Oluyemi Okupe sold 9,067 shares of the company’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total transaction of $275,092.78. Following the sale, the chief financial officer directly owned 91,617 shares of the company’s stock, valued at $2,779,659.78. This represents a 9.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Michael Chi sold 13,750 shares of the stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total transaction of $504,762.50. Following the sale, the chief operating officer owned 305,161 shares in the company, valued at approximately $11,202,460.31. This trade represents a 4.31% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 80,463 shares of company stock worth $2,846,696 over the last 90 days. Company insiders own 17.71% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on HIMS shares. Morgan Stanley lowered their price objective on Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. TD Cowen lowered their price target on Hims & Hers Health from $20.00 to $17.00 and set a “hold” rating for the company in a report on Tuesday, February 24th. BTIG Research downgraded Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Citigroup raised shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and upped their target price for the company from $13.25 to $24.00 in a research report on Tuesday, March 10th. Finally, Barclays increased their target price on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 11th. Three research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $30.75.

Hims & Hers Health Price Performance

HIMS opened at $24.74 on Monday. The stock’s 50-day moving average price is $23.84 and its 200 day moving average price is $37.34. Hims & Hers Health, Inc. has a 12-month low of $13.74 and a 12-month high of $70.43. The firm has a market cap of $5.64 billion, a price-to-earnings ratio of 48.51, a PEG ratio of 2.34 and a beta of 2.56. The company has a current ratio of 1.90, a quick ratio of 1.70 and a debt-to-equity ratio of 1.80.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 23rd. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.06. The company had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.Hims & Hers Health’s revenue was up 28.4% compared to the same quarter last year. During the same period in the previous year, the company posted $0.11 EPS. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its board has initiated a share buyback plan on Monday, November 17th that authorizes the company to repurchase $250.00 million in shares. This repurchase authorization authorizes the company to repurchase up to 3% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s management believes its stock is undervalued.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Novo Nordisk pact ends lawsuit and establishes a commercial pathway for Ozempic and Wegovy on Hims’ platform — the agreement removes a major legal overhang and directly boosts revenue and credibility expectations. Hims shares notch record week as Novo pact spurs optimism
• Positive Sentiment: Several broker notes and price‑target/upside forecasts have followed the Novo news, including bullish coverage that highlights strong upside potential and helped drive volume. Barclays Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock
• Positive Sentiment: Pre‑market and intraday rallies (big volume spikes) reflected momentum traders buying the Novo settlement and analyst upgrades. Hims & Hers Health shares rally continues, up 7% in premarket Thursday
• Neutral Sentiment: Bank of America moved its coverage (raised to Neutral), and other firms are re‑rating the stock; analyst interest increases liquidity but opinions differ on valuation and risks. Hims & Hers Health (NYSE:HIMS) Raised to Neutral at Bank of America
• Neutral Sentiment: Corporate hires (communications leader) and company messaging improvements aim to steady the narrative as the Novo story evolves — helps investor relations but not an immediate earnings driver. Hims & Hers Adds Communications Leader As Expansion And Novo Story Evolve
• Negative Sentiment: Regulatory and margin pressures remain a material risk: FDA crackdown on compounded GLP‑1 formulations, prior warning letters and potential enforcement actions have pressured sentiment and valuation. Is Hims & Hers Really the Growth Stock to Buy That It Appears?
• Negative Sentiment: Shares have been down sharply over recent months and saw volatility around company headlines; some outlets flagged a ~29% three‑month decline and one‑day drops that reflect lingering execution and margin concerns. Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
• Negative Sentiment: Short‑term pullbacks (including a recent ~7.9% one‑day drop) show that headline risk still drives outsized moves; investors should weigh upside from the Novo deal against execution, regulatory and margin risks. Here’s Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.